business

AstraZeneca Novo Nordisk Amgen Pfizer Eli Lilly

Drugmakers Compete to Innovate in Obesity Treatment Market with New GLP-1 Pills and Alternative Therapies

The race among drugmakers to develop innovative obesity treatments is intensifying, with Eli Lilly and Novo Nordisk leading the market while new entrants explore alternative therapies. This competition is crucial as it could reshape the landscape of weight-loss medications and impact pricing and accessibility for patients.